10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Late complications of transcatheter atrial septal defect closure requiring urgent surgery

      brief-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction Transcatheter atrial septal defect (ASD) closure has become a widely applied procedure – the recommended method of therapy in eligible patients due to the improved learning curve, cosmetic benefits and shorter recovery time [1]. Although the performance and safety of these devices appear to be reliable, certain risks and complications remain. Case reports Case 1 A 21-year-old female patient was transferred to our hospital after being diagnosed with massive pulmonary thromboembolism (PTE). Three years prior to admission, she underwent transcatheter closure of the secundum ASD with a 33 mm CardioSEAL-StarFLEX occluder (NMT Medical, Boston, MA, USA). A year ago, she was involved in a car accident and sustained significant blunt chest trauma. Transthoracic echocardiography confirmed the presence of thrombi in the right atrium and the pulmonary artery, with massive dilatation of the right ventricle and the pulmonary artery, along with severe pulmonary hypertension. Also, protrusion or dislodgement of the occluder was suspected. Her deteriorated clinical conditions warranted immediate surgery. The patient was put on a cardiopulmonary bypass (CPB) and the right atrium and the pulmonary artery were opened. Several thrombi were removed, the largest being 2 × 3 cm. The ASD occluder was identified with a thrombus attached to it and evident device-arm fracture (Figure 1). The occluder underwent almost complete healing with full endocardium covering except in the rim area. The device was removed and the ASD was repaired with a patch. Unfortunately, due to right heart failure, the patient could not be successfully weaned from the CPB, not even after an artificially created interatrial shunt, and she expired. Figure 1 A, B – Trans-esophageal echocardiography demonstrating a mass in the right atrium and detached device, C, D – intraoperative finding Although one cannot say with absolute certainty that massive PTE developed because of device-related thrombosis, it seems intuitive that blood turbulence around the protruded umbrella and device-arm fracture could have acted as a nidus for repeated thrombus formation with subsequent embolization. The occluder malfunction (fracture) was most likely the result of sustained blunt chest trauma a year prior to admission. We hypothesize that the sudden increase in intrathoracic pressure during trauma as well as direct compression on the heart generated a point of high wall stress around the occluder’s septal insertion, which may have led to device fracture and dislodgment. Case 2 A 32-year-old female patient was referred to our hospital with the diagnosis of acute aortic dissection. She complained of a sharp tearing pain in the chest and back with a loss of consciousness. A year prior to admission, she underwent ASD closure with a 26 mm Amplatzer occluder (St. Jude Medical, Minneapolis, MN, USA) in another hospital. Chest computed tomography was performed showing massive pericardial effusion and no clear origin of contrast extravasation, and no signs of intimal flap throughout the aorta. Due to a cardiac tamponade and deteriorated clinical conditions, the patient was rushed to surgery where she arrested during anesthesia induction and recovered upon pericardial incision and evacuation of 400 ml of blood. She was put on a CPB and the aortic root erosion in the region of non-coronary cusp was identified (Figure 2). No signs of other aortic pathology (dissection) were evident. The tear was sutured with two pledgeted sutures. The right atrium was opened with no signs of thrombi. The Amplatzer occluder was in close relation to the roof of the atria, and consequently the aortic root, and was undoubtedly the cause of the aortic perforation. It was extracted and the ASD was repaired with a patch. She made an uneventful recovery and was discharged home on the 8th postoperative day. Figure 2 A, B – Computerized tomography showing the position of the device and pericardial effusion, C – extraction of Amplatzer device, D – aortic root erosion, E – extracted device Discussion Transcatheter closure of ASD is the recommended method of treatment in patients with suitable defect anatomy (class I) [2, 3]. Due to inherent design properties (size, shape, material, and construction), every device is associated with a specific type of complications, which are potentially life threatening. Complications commonly associated with ASD closure device include residual shunts, embolization, device-related thrombosis, erosion and perforation of the heart, infective endocarditis, and sudden death. Perforation is the most feared complication described in the literature with the incidence of device erosion in the United States around 0.1% [4]. Perforation is most likely to happen during the first 48 h after the procedure and it is rarely manifested as a late complication. Perforation usually develops on the atrial dome and the adjacent aorta. Patients can present with haemopericardium, pericardial effusion, cardiovascular collapse, and sudden cardiac death. The U.S. Food and Drug Administration issued a warning about safety issues encountered with Amplatzer septal occluder devices stating that these devices may cause life-threatening tissue erosion inside the heart requiring immediate surgery. Several mechanisms on how the device may lead to perforation were proposed [4]. Deficient rims in vulnerable areas could increase the chance of contact between the device and the atrial wall in the same manner as the oversizing of a device. Device-related thrombosis has been reported in many series with the incidence of thrombus formation of 1.2% in ASD patients [5]. The incidence of thrombus formation is highest during the first 4 weeks after device implantation and is extremely rare after 8–12 months. The specific design of the CardioSEAL-StarFLEX device (a metallic framework with Dacron fabric) rendered them prone to thrombosis as well as stress-mediated device arm fractures. The case of late thrombus formation demonstrated in our patient occurred following major blunt chest trauma that might have led to device-arm fracture that, in turn, could have acted as a nidus for repeated thrombus formation. Specifically, the majority of thrombi were found around the rim area of the occluder (fractured wires) – an area with no complete healing and endothelialization. Usually, thrombi resolve spontaneously after anticoagulation therapy with heparin or warfarin, although some thrombi require surgical intervention, as demonstrated in our case. A longer period of surveillance after device ASD closure might be warranted in order to capture late occurrence of device malfunction, which may be associated with thromboembolic events. Conflict of interest The authors declare no conflict of interest.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Early and late complications associated with transcatheter occlusion of secundum atrial septal defect.

          The goal of this study was to report the early and late complications experienced in atrial septal defect (ASD) transcatheter closure. Atrial septal defect transcatheter occlusion techniques have become an alternative to surgical procedures. A number of different devices are available for transcatheter ASD closure. The type and rate of complications are different for different devices. Between December 1996 and January 2001, 417 patients (mean age: 26.6 +/- 19 years) underwent transcatheter occlusion of secundum type ASD. Complications were categorized into major and minor. Two different devices were used: the CardioSEAL/STARFlex in 159 patients and the Amplatzer septal occluder in 258 patients. Thirty-four patients experienced 36 complications during the hospitalization (8.6%, 95% confidence interval: 6.1% to 11.1%). Ten patients underwent elective surgical repair because of device malposition (three patients) or device embolization (seven patients). Twenty-four patients experienced 25 minor complications: unsatisfactory device position or embolization. Devices were retrieved using a gooseneck snare and/or a basket; 11 patients experienced arrhythmic problems. Other complications were: pericardial effusion, thrombus formation on the left atrial disc, right iliac vein dissection, groin hematoma, hemorrhage in the retropharynx and sizing balloon rupture. Two patients had late complications: peripheral embolization in the left leg one year after implantation of an Amplatzer device and sudden death 1.5 year later. Our series of patients with ASD by transcatheter occlusion shows that the procedure is safe and effective in the vast majority of cases. To further reduce the complications rate, the criteria of device selection according to ASD morphology and some technical tips during implantation are discussed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients.

            The purpose of this study was to investigate the incidence, morphology, and clinical course of thrombus formation after catheter closure of intra-atrial shunts. Post-procedure detailed information about thrombotic material on different devices for transcatheter closure is missing. A total of 1,000 consecutive patients were investigated after patent foramen ovale (PFO) (n = 593) or atrial septal defect (ASD) (n = 407) closure. Transesophageal echocardiography (TEE) was scheduled after four weeks and six months. Additional TEEs were performed as clinically indicated. Thrombus formation in the left atrium (n = 11), right atrium (n = 6), or both (n = 3) was found in 5 of the 407 (1.2%) ASD patients and in 15 of the 593 (2.5%) PFO patients (p = NS). The thrombus was diagnosed in 14 of 20 patients after four weeks and in 6 of 20 patients later on. The incidence was: 7.1% in the CardioSEAL device (NMT Medical, Boston, Massachusetts); 5.7% in the StarFLEX device (NMT Medical); 6.6% in the PFO-Star device (Applied Biometrics Inc., Burnsville, Minnesota); 3.6% in the ASDOS device (Dr. Ing, Osypka Corp., Grenzach-Wyhlen, Germany); 0.8% in the Helex device (W.L. Gore and Associates, Flagstaff, Arizona); and 0% in the Amplatzer device (AGA Medical Corp., Golden Valley, Minnesota). The difference between the Amplatzer device on one hand and the CardioSEAL device, the StarFLEX device, and the PFO-Star device on the other hand was significant (p < 0.05). A pre-thrombotic disorder as a possible cause of the thrombus was found in two PFO patients. Post-procedure atrial fibrillation (n = 4) and persistent atrial septal aneurysm (n = 4) had been found as significant predictors for thrombus formation (p < 0.05). In 17 of the 20 patients, the thrombus resolved under anticoagulation therapy with heparin or warfarin. In three patients, the thrombus was removed surgically. The incidence of thrombus formation on closure devices is low. The thrombus usually resolves under anticoagulation therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk.

              The objectives of this study were to identify possible risk factors that may lead to erosion of the Amplatzer septal occluder (ASO) and recommend ways to minimize future risk. There have been rare occurrences of adverse events with development of pericardial effusion after ASO placement. Identification of high-risk cases, early recognition, and prompt intervention may minimize the future risks of adverse events. In all patients who developed hemodynamic compromise after ASO placement, echocardiograms (pre-, intra-, and postprocedure), atrial septal defect (ASD) size (nonstretched, stretched), size of the device used, cineangiograms, and operative records were reviewed by a panel selected by AGA Medical Corporation. The findings were compared to the premarket approval data obtained from FDA-approved clinical trials that were conducted in the United States, before the device was approved. A total of 28 cases (14 in United States) of adverse events were reported to AGA Medical. All erosions occurred at the dome of the atria, near the aortic root. Deficient aortic rim was seen in 89% and the defect described as high ASD, suggesting deficient superior rim. The device to unstretched ASD ratio was significantly larger in the adverse event group when compared to the FDA trial group. The incidence of device erosion in the United States was 0.1%. The risk of device erosion with ASO is low and complications can be decreased by identifying high-risk patients and following them closely. Patients with deficient aortic rim and/or superior rim may be at higher risk for device erosion. Oversized ASO may increase the risk of erosion. The defect should not be overstretched during balloon sizing. Patients with small pericardial effusion at 24 hr should have closer follow-up. (c) 2004 Wiley-Liss, Inc.
                Bookmark

                Author and article information

                Journal
                Postepy Kardiol Interwencyjnej
                Postepy Kardiol Interwencyjnej
                PWKI
                Postępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
                Termedia Publishing House
                1734-9338
                1897-4295
                29 November 2017
                2017
                : 13
                : 4
                : 335-338
                Affiliations
                [1 ]Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
                [2 ]Institute of Cardiovascular Diseases Vojvodina, Sremska Kamenica, Serbia
                Author notes
                Corresponding author: Lazar Velicki MD, PhD, Institute of Cardiovascular Diseases Vojvodina, Put doktora Goldmana 4, 21204 Sremska Kamenica, Serbia. phone: +381 21 4805701. fax: +381 21 6622059. e-mail: lazar.velicki@ 123456mf.uns.ac.rs
                Article
                31048
                10.5114/aic.2017.71617
                5770866
                29362578
                e54f026e-aab3-48aa-8b60-8f6d721e3839
                Copyright: © 2017 Termedia Sp. z o. o.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

                History
                : 19 September 2017
                : 28 October 2017
                Categories
                Short Communication

                Comments

                Comment on this article